About
This group is mostly dedicated to research on biomarkers and molecular mechanisms underlying the development and progression of malignant neoplasms and it aims to provide translational knowledge to advance the diagnosis, prognosis and prediction of a variety of human cancers.
For this purpose, the team combines both morphological (light and ultrastructural microscopy) and advanced molecular tools including next generations sequencing (NGS), in situ hybridisation and immunohistochemistry; these, integrated with bioinformatics tools such as digital pathology, provide a multidisciplinary approach to cancer research. They also have a special interest, and long and productive research tradition in non-neoplastic conditions, including neurodegenerative diseases including dementias and nephropathology amongst others.
The group of Cancer Molecular Pathology and Vulnerabilities (CAMOPAVUL) has been recognized as a Consolidated Research Group (2021SGR01490) with financial support by the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia.
Keywords: Cancer, NGS, molecular pathology, traslational research.
Group Leader
Team
Lorena Valdivieso Almeida(ELIMINAR)
Ana Maria Muñoz Marmol(ELIMINAR)
Aintzane Urbizu Serrano(ELIMINAR)
Laura Arnaldo Orts(ELIMINAR)
Laura Pons Martínez(ELIMINAR)
Laura Hernández León(ELIMINAR)
Alba Hernández Gallego(ELIMINAR)
Ariadna Quer Pi-Sunyer(ELIMINAR)
Carolina Sanz Monte(ELIMINAR)
Cristina Carrato Moñino(ELIMINAR)
Gustavo Tapia Melendo(ELIMINAR)
Andrea Feu Llaurado(ELIMINAR)
Raquel López Martos(ELIMINAR)
Pedro Luís Fernández Ruiz(ELIMINAR)
José Luís Mate Sanz(ELIMINAR)
Mireya Jimeno Ramiro(ELIMINAR)
Paula Rodríguez Martínez(ELIMINAR)
Marta Ávila Terzi(ELIMINAR)
Eva Castellà Fernández(ELIMINAR)
Juan Pablo Fernández Romero(ELIMINAR)
Paula Osorio Recordà(ELIMINAR)
Eva Fernández López(ELIMINAR)
Research lines
Breast and genitourinary neoplasms
Pedro L. Fernández, M. Carmen Gómez-Plaza, Eva Castellá, Cristina Carrato
Lymphoid and mesenchymal neoplasms
Gustavo Tapia, José L. Mate, Caterina Fumagalli
Respiratory tract, and head & neck neoplasms
José L. Mate, Alba Hernández, Ariadna Quer
Digestive and hepatobiliary tract neoplasms
Raquel López, Alba Hernández, Laura Hernández, Caterina Fumagalli
Nervous and endocrine systems neoplasms, and neurodegenerative disorders
Cristina Carrato, Aurelio Ariza, Katrin Beyer
Skin neoplasms
Ariadna Quer, Caterina Fumagalli, Paula Rodriguez
Nefropathology and fetal pathology
Dolores López Álvarez, Paula Rodriguez, Marta Ávila
Molecular pathology
A Muñoz, Carolina Sanz
Paleopathology
Pedro L. Fernández
Active projects
Molecular characterization of genomics and phenotypical patterns related to resistance to neoadjuvant therapy in triple negative and Her2 positive breast carcinomas
PI: Pedro L. Fernández
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI19/01371
Start Date: 01/01/2020
End Date: 31/12/2022
Comprehensive molecular and microspectroscopic profiling of breast carcinomas and their resistance to neoadjuvant treatment
PI: Pedro L. Fernández
Funding agency: La Marató de TV3
Agency code: 567/2019
Start Date: 01/01/2020
End Date: 31/12/2022
Análisis epigenómico integral del linfoma plasmablástico: identificación de características epigenéticas para mejorar el diagnóstico y pronóstico de los pacientes
PI: José Tomás Navarro
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI19/01588
Start Date: 01/01/2020
End Date: 31/12/2022
Validación de las alteraciones genómicas en el glioblastoma: búsqueda de puntos débiles para intervención terapéutica (VAL-GLIO-THERINT)
PI: Cristina Carrato
Funding agency: Instituto de Salud Carlos III (ISCIII)
Start Date: 01/01/2022
End Date: 31/12/2024
Scientific publications
Felip E, Gutiérrez-Chamorro L, Gómez M, Garcia-Vidal E, Romeo M, Morán T, Layos L, Pérez-Roca L, Riveira-Muñoz E, Clotet B, Fernandez PL, Mesía R, Martínez-Cardús A, Ballana E, Margelí M. Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers (Basel). 2022 Jan 27;14(3):641. DOI: 10.3390/cancers14030641. PMID: 35158911; PMCID: PMC8833711.
Fernández PL, Rodriguez P, Margeli M, Sanz C, Muñoz AM, Urbizu A, Quiroga V, Castillo A, Cirauqui B, Teruel I, Castella E, Felip E, Perello C, Pons L, Leon LH. Characterization of Residual TN and HER2 Breast Carcinomas after Neoadjuvant Therapy. Modern Patology. 2022 Mar 1.
Temprana-Salvador J, López-García P, Castellví Vives J, de Haro L, Ballesta E, Rojas Abusleme M, Arrufat M, Marques F, Casas JR, Gallego C, Pons L, Mate JL, Fernández PL, López-Bonet E, Bosch R, Martínez S, Ramón Y Cajal S, Matias-Guiu X. DigiPatICS: Digital Pathology Transformation of the Catalan Health Institute Network of 8 Hospitals-Planification, Implementation, and Preliminary Results. Diagnostics (Basel). 2022 Mar 30;12(4):852. DOI: 10.3390/diagnostics12040852. PMID: 35453900; PMCID: PMC9025604.
Pons L, Hernández-León L, Altaleb A, Ussene E, Iglesias R, Castillo A, Rodríguez-Martínez P, Castella E, Quiroga V, Felip E, Cirauqui B, Margelí M, Fernández PL. Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. Sci Rep. 2022 May 17;12(1):8176. DOI: 10.1038/s41598-022-11411-5. PMID: 35581229; PMCID: PMC9114341.
News
Conclouen amb èxit les visites de La Marató als laboratoris de l’IGTP
Les quatre visites del cicle "Visita la recerca" de la Fundació La Marató de TV3 a l'Institut de Recerca Germans Trias i Pujol (IGTP) han finalitzat amb un balanç molt positiu. Més de 50 col·laboradors han pogut conèixer diversos projectes de recerca finançats a través d'aquesta iniciativa solidària.
Es presenta CARE el Programa Translacional de Recerca en Càncer de l’IGTP
CARE, el Programa Translacional de Recerca en Càncer (Translational Program in Cancer Research), és el primer programa transversal promogut per l'Institut de Recerca Germans Trias i Pujol (IGTP), que vol ser nexe d'investigadors del càncer interessats a establir ponts entre la recerca bàsica i la clínica, amb una clara vocació per traslladar al pacient el coneixement i les eines que es generen al laboratori.
Contact
Pedro Luis Fernández Ruiz
(+34) 93 497 8356 extn. 3059